PATAS, a first-in-class therapeutic peptide biologic, improves whole-body insulin resistance and associated comorbidities in vivo.
Schreyer, Edwige Obringer, Cathy Messaddeq, Nadia Kieffer, Bruno Zimmet, Paul Fleming, Alexander Geberhiwot, Tarekegn Marion, Vincent
Schreyer, Edwige
Obringer, Cathy
Messaddeq, Nadia
Kieffer, Bruno
Zimmet, Paul
Fleming, Alexander
Geberhiwot, Tarekegn
Marion, Vincent
Citations
Altmetric:
Affiliation
Other Contributors
Publication date
2022-09-01
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Adipose tissue is a key regulator of whole-body metabolic fitness because of its role in controlling insulin sensitivity. Obesity is associated with hypertrophic adipocytes with impaired glucose absorption, a phenomenon existing in the ultrarare monogenic disorder Alström syndrome consisting of severe insulin resistance. Inactivation of ALMS1 directly inhibits insulin-mediated glucose absorption in the white adipose tissue and induces severe insulin resistance, which leads to type 2 diabetes, accelerated nonalcoholic liver disease, and fibrosis. These phenotypes were reversed by specific adipocyte-ALMS1 reactivation in vivo. Subsequently, ALMS1 was found to bind to protein kinase C-α (PKCα) in the adipocyte, and upon insulin signaling, PKCα is released from ALMS1. α-Helices in the kinase domain of PKCα were therefore screened to identify a peptide sequence that interfered with the ALMS1-PKCα protein interaction. When incubated with cultured human adipocytes, the stapled peptide termed PATAS, for Peptide derived of PKC Alpha Targeting AlmS, triggered insulin-independent glucose absorption, de novo lipogenesis, and cellular glucose utilization. In vivo, PATAS reduced whole-body insulin resistance, and improved glucose intolerance, fasting glucose, liver steatosis, and fibrosis in rodents. Thus, PATAS represents a novel first-in-class peptide that targets the adipocyte to ameliorate insulin resistance and its associated comorbidities.
Citation
Schreyer E, Obringer C, Messaddeq N, Kieffer B, Zimmet P, Fleming A, Geberhiwot T, Marion V. PATAS, a First-in-Class Therapeutic Peptide Biologic, Improves Whole-Body Insulin Resistance and Associated Comorbidities In Vivo. Diabetes. 2022 Sep 1;71(9):2034-2047. doi: 10.2337/db22-0058
Type
Article